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Abstract 
Distearoyl-N-(3-carboxypropionoyl poly(ethylene glycol) succinyl)phosphatidylethanolamine (DSPE-PEG-COOH) was newly synthe- 
sized and used to prepare novel immunoliposomes carrying monoclonal antibodies at the distal ends of the PEG chains (Type C). 
Liposomes were prepared from egg phosphatidylcholine (ePC) and cholesterol (CH) (2:1, m/m) containing 6 mol% of DSPE-PEG-COOH, 
and a monoclonal IgG antibody, 34A, which is highly specific to pulmonary endothelial cells, was conjugated to the carboxyl groups of 
DSPE-PEG-COOH to give various amounts of antibody molecules per liposome. Other immunoliposomes with PEG coating (Type B) or 
without PEG coating (an earlier type of immunoliposome, Type A) were prepared for comparison. The average molecular weight of PEG 
in Type B or C immunoliposomes was 2000. Type B and Type C liposomes without antibodies howed prolonged circulation time and 
reduced reticulo-endothelial system (RES) uptake owing to the presence of PEG. These three different ypes of 34A-immunoliposomes 
with 30-35 antibody molecules per vesicle were injected into mice to test the immunotargetability to the lung. The efficiency of lung 
binding of 34A-Type B was one-half of that of 34A-Type A, though a large amount of 34A-Type B remained in the blood circulation for 
a long time, suggesting that the steric hindrance of PEG chains reduced not only the immunospecific antibody-antigen bi ding, but also 
the RES uptake. The degree of lung binding of 34A-Type C was about 1.3-fold higher than that of 34A-Type A, indicating that 
recognition by the antibodies attached to the PEG terminal was not sterically hindered and that the free PEG (i.e., that not carrying 
antibody) was effective in increasing the blood concentration f immunoliposomes by enabling them to evade RES uptake. The latter 
phenomenon was confirmed by using nonspecific antibody-Type C immunoliposomes (14-Type C), which showed a high blood level for 
a long time. Our approach provides a simple means of conjugating antibodies directly to the distal end of PEG which is already bound to 
the liposome membrane, and should contribute to the development of superior targetable drug delivery vehicles for use in diagnostics and 
therapy. 
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1. Introduction 
Drug delivery to specific cells by immunoliposomes 
represents a potentially attractive mode of therapy. How- 
ever, though immunoliposomes are effective in specific 
binding to target cells in vitro, their targeting efficiency in 
vivo is relatively low. Studies in vivo have revealed that 
coating liposomes with antibody (Type A in Fig. 1) leads 
to enhanced uptake of the immunoliposomes by the retic- 
uloendothelial system (RES) [1,2] and the immunotar- 
getability depends on the antibody density on the surface 
[3]. Thus, highly efficient target binding and a relatively 
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Fig. 1. Schematic illustration ofimmobilization f antibody on liposomes. 
Type A: PEG-free immunoliposomes with antibody covalently linked to 
the short anchor NGPE; Type B: PEG-immunoliposomes with antibody 
covalently linked to NGPE; Type C: new type of PEG-immunoliposomes 
with antibody attached tothe distal terminal of DSPE-PEG-COOH. 
ison with those of Type A and B immunoliposomes. The 
monoclonal antibody 273-34A (34A), specific for the pul- 
monary endothelial cells of mouse [13], was used in this 
study. 34A recognize surface glycoproteins, gpll2, which 
are expressed exclusively and abundantly on the lumenal 
surface of the pulmonary capillary vessel wall in mouse 
lung [14]. It has been shown that 34A-immunoliposomes 
(Type A) gain direct access and bind efficiently to the lung 
target in vivo [3,13], so this model should allow a conve- 
nient test of our hypothesis. 
Blume et al. [15] have recently coupled plasminogen to 
liposomes using a similar technique. However, little is 
known about antibody-mediated liposomal targeting in this 
system. 
low level of RES uptake of the immunoliposomes are 
apparently mutually exclusive. 
Recently, long-circulating liposomes have been pre- 
pared by coating the liposome surface with ganglioside 
GM1 (GM1) or amphipathic poly(ethylene glycol) (PEG) 
[4-8]; this coating allows the liposomes to evade RES 
uptake and remain in the', systemic irculation for a long 
period of time, which should maximize targeting. We have 
shown that incorporation of ganglioside GM1 (GM1) can 
significantly enhance the target binding of immunolipo- 
somes, whereas amphipathic PEG with an average molecu- 
lar weight of 5000 actually inhibits it [9-11]. These results 
can be explained in terms of their steric barrier activity, 
which is measured by a liposome agglutination assay. 
Surface PEG polymers (Type B in Fig. 1) hinder the 
binding of liposome-bound antibodies with target antigens, 
while GM1 presents a much weaker steric barrier. The 
presence of GM1 on liposome surface is apparently suffi- 
cient to prevent rapid uptake by macrophages, without 
hindering antibody-antigen binding. Thus, the elevated 
blood concentration of liposomes containing GM1 kineti- 
cally enhances the target binding of immunoliposomes [9], 
but the same effect provided by amphipathic PEG does not 
lead to an enhanced talget binding. Nevertheless, PEG 
remains of interest bec~mse of its ease of preparation, 
relatively low cost, controllability of molecular weight and 
linkability to lipids by a variety of methods as compared 
with GM1 molecules. 
It has been proposed by us [10] and Klibanov and 
Huang [12] that antibodies could be attached to the distal 
ends of PEG chains which are already bound to the 
liposome membrane (Type C in Fig. 1). Since the binding 
of the antibody to the target cell should not be sterically 
hindered by the PEG chains in this situation, the immuno- 
liposomes should show more efficient target binding. 
Herein, to test this hypolhesis, we have synthesized novel 
distearoyl phosphatidylethanolamine derivatives of PEG 
with terminal COOH groups for the preparation of Type C 
immunoliposomes. The targetability and biodistribution of 
Type C immunoliposomes were studied in mice in compar- 
2. Materials and methods 
2.1. Materials 
Egg phosphatidylcholine ( PC), distearoylphosphatid- 
ylethanolamine (DSPE), monomethoxy poly(ethylene gly- 
col) succinimidyl succinate (PEG-OSu), and poly(ethylene 
glycol) bis(succinimidyl succinate) (PEG-2OSu) were 
kindly donated by Nippon Oil and Fats (Tokyo, Japan). 
The number-average molecular weight (Mn), weight-aver- 
age molecular weight (M w) and polydispersity (Mw/M .)  
of PEG-OSu and PEG-2OSu were measured by means of 
gel permeation chromatography (Shodex KF801, KF803 
and KF804 combination columns). The values of M n of 
PEG-OSu and PEG-2OSu were 2219 and 2230, respec; 
tively and their polydispersities were 1.03 and 1.04, re- 
spectively. Cholesterol (CH), triethylamine, and glutaric 
acid anhydride were purchased from Wako Pure Chemi- 
cals (Osaka, Japan). 1-Ethyl-3-(3-dimethylamino- 
propyl)carbodiimide (EDC), N-hydroxysulfosuccinimide 
(S-NHS) and IODO-GEN were obtained from Pierce 
(Rockford, IL). 67GAC13 was kind gift from Dr. Umeda 
(Teikyo University), and 1251 was obtained from New 
England Nuclear Japan (Tokyo). 
N-Glutaryldistearoylphosphatidylethanolamine (NGPE), 
which was used for preparation of Type A and B immuno- 
liposomes, was synthesized by the method of Weissig et 
al. [16]. Distearoyl-N-(monomethoxy poly(ethylene glycol) 
succinyl)phosphatidylethanolamine (DSPE-PEG) was syn- 
thesized as described [8]. 
2.2. Monoclonal antibody 
Rat monoclonal IgG2~ antibody 34A and rat monoclonal 
IgG2a antibody 14, a subtype-matched nonspecific ontrol 
antibody, were prepared as described [13]. All antibodies 
were isolated from Fischer F344 rats after immunization 
with Balb/c mouse lung homogenate. Antibodies were 
radiolabeled with 1251, using the IODO-GEN method, to a 
specific activity of (2-5)- 10 5 cpm//xg. 
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2.3. Synthesis of DSPE-PEG-COOH 
Distearoyl-N-(3-carboxypropionoyl p ly(ethylene gly- 
col) succinyl)phosphatidylethanolamine (DSPE-PEG- 
COOH) was synthesized by a modification of the method 
used for DSPE-PEG [8]. In brief, 1 ml of 5% DSPE in 
CHC13/methanol (3:1 v/v)  was added to 9.5 ml of 10% 
PEG-2OSu in CHC13, followed by addition of 20.5 /zl of 
triethylamine. The reaction mixture was stirred vigorously 
overnight at 35°C under protecting from light. Full conver- 
sion of the primary amino group in DSPE was confirmed 
by the negative ninhydrin reactivity after separation of the 
products by TLC. Phospholipid phosphorus assay [17] 
showed the appearance of a new phosphate-positive spot at 
a higher Rf value than that of DSPE. A small amount of 
water was added to the evaporated reaction residues to 
form micelles. The DSPE-PEG-COOH micelles were dia- 
lyzed for 5 days against water using a dialysis bag with 
large pores (Spectra-por CE 300000 MWCO, Spectrum 
Medical) and then lyophilized. The yield of DSPE-PEG- 
COOH was approx. 180 mg. 
2.4. Preparation of immunoliposomes 
The plain liposomes for preparing Type A or Type C 
immunoliposomes were composed of ePC/CH (2:1, m/m) 
with 6 mol% of NGPE or DSPE-PEG-COOH, respec- 
tively. The plain liposomes for Type B were composed of 
ePC/CH (2:1, m/m), with 6 tool% of DSPE-PEG and 6 
mol% of NGPE. As a tracer, 67Ga bound to DF (Desferal ®, 
Ciba-Geigy, Japan) was used (67Ga-DF). Small unilamellar 
liposomes (SUV, 90-130 nm in diameter) were prepared 
by the reverse-phase evaporation method [18] followed by 
extrusion (Lipex Biomembranes, Canada) through two 
stacked Nuclepore filters (0.1 /zm). Normal saline was 
used as the liposomal aqueous phase. The extruded lipo- 
somes were then chromatographed to remove unencapsu- 
lated 67Ga-DF on a Bio-Gel A-1.5m column (Bio-Rad), 
which was equilibrated and eluted with Mes buffer (10 
mM Mes/150 mM NaCI, pH 5.5). The liposome fraction 
was diluted to 10 /~mol lipid/ml with Mes buffer. The 
average size of the liposomes was measured with a Nicomp 
370 HPL submicron particle analyzer (Particle Sizing Sys- 
tems, Santa Barbara, CA). 
Coupling of antibodies to the plain liposomes to prepare 
Type A and B immunoliposomes was performed as de- 
scribed [10]. The Type C immunoliposomes were prepared 
similarly. Briefly, to 300 /zl of the plain liposomes (3 
/~mol lipids) in Mes buffer, 120 /zl of 0.25 M EDC in 
water and 120 /xl of 0.25 M S-NHS in water were added, 
and the mixture was incubated for 10 min at room temper- 
ature. The mixture was neutralized with 1 M NaOH to pH 
7.5. The desired amount of antibody with a trace amount 
of 125I-labeled antibody was then added and the whole was 
incubated for 8 h at 4°C with gentle stirring. The immuno- 
liposomes were separated from the unbound protein on a 
Bio-Gel A-15m column preequilibrated with saline. Peak 
fractions containing immunoliposomes luted in the void 
volume were collected, pooled, and diluted to an appropri- 
ate volume with saline. The lipid concentration and the 
coupling efficiency of antibody were estimated by the 
phosphorus assay [19] and the radioactivity of 1251, respec- 
tively. The average number of antibody molecules per 
liposome was calculated by using the above values and the 
following assumptions: molecular weight of antibody is 
150000; the average number of phospholipid molecules 
per liposome is estimated by the method of Enoch and 
Strittmatter [20]. 
2.5. Biodistribution studies 
Immunoliposomes were injected into Balb/c mice (6- 
to 7-week-old male mice, Sankyo, Tokyo) via the tail vain. 
Approx. 200 /.tl of immunoliposomes was injected into 
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Fig. 2. Blood clearance (A) and biodistribution at6 h (B) of liposomes after intravenous injection. Liposomes (90-130 nm average diameter) composed of 
ePC/CH (2:1, m/m), ePC/CH/DSPE-PEG (2:1:0.19, m/m)  or ePC/CH/DSPE-PEG-COOH (2:1:0.19, m/m)  were labeled with 67Ga-DF. Data are 
expressed as mean + S.D. (n = 3). * is 0.1 + 0.03 (% of dose in heart). 
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each mouse, and at intervals, mice were lightly anes- 
thetized and bled by eye puncture. Blood was collected 
and weighed. Mice were killed by cervical dislocation and 
dissected. Organs were collected, weighed, and analyzed 
for 67Ga radioactivity in a gamma counter. The results are 
presented as the percentage of the total injected dose for 
each organ. The total radioactivity in the blood was deter- 
mined by assuming that the total volume of blood was 
7.3% of the body weight [21]. Values for organs were 
corrected for blood contamination [22]. 
3. Results 
3.1. Biodistribution studie~ of DSPE-PEG-COOH-contain- 
ing, antibody-free liposomes 
DSPE-PEG derivatives with a reactive group (carboxyl 
group) at the distal terminal of PEG chains (DSPE-PEG- 
COOH, Fig. 2) were synthesized by hydrolysis of distea- 
royl-N-(monosuccinimidyl succinoyl poly(ethylene glycol) 
succinyl)phosphatidyletha:aolamines. The purified DSPE- 
PEG-COOH showed a single spot of Rf 0.31 on TLC with 
CHC13/MeOH/H20 (70:30:5, v/v).  
To test whether DSPE-PEG-COOH can prolong the 
circulation time of liposomes, 67Ga-DF-labeled SUV (di- 
ameter 90-130 nm) of three different compositions were 
prepared and injected into Balb/c mice via the tail vein: 
ePC/CH (2:1, m/m), ePC/CH/DSPE-PEG (2:1:0.19, 
m/m)  and ePC/CH/DSPE-PEG-COOH (2:1:0.19, m/m). 
As shown in Fig. 2, liposomes composed of ePC/CH (2:1 
molar ratio) were rapidly cleared from the blood (panel A) 
and were found almost entirely in the liver (panel B). 
Addition of DSPE-PEG o1: DSPE-PEG-COOH to ePC/CH 
liposomes greatly prolonged the liposome residence in the 
circulation (Fig. 2). The values of tl/2 for liposome blood 
clearance were estimated to be 1.5 h, 5.6 h and 6.4 h for 
ePC/CH liposomes and liposomes containing DSPE-PEG 
and DSPE-PEG-COOH, respectively. Thus, DSPE-PEG- 
COOH significantly enhanced the blood residence time of 
the liposomes, regardless of the presence of the terminal 
carboxyl group. There were no marked differences in 
tissue distribution between liposomes containing DSPE- 
PEG and DSPE-PEG-COOH (Fig. 2B). 
3.2. Immunotargetability and biodistribution of type A, B 
or C immunoliposomes in mice 
To test the effect of both the position of the antibody 
and the steric hindrance of PEG chains on the behavior of 
immunoliposomes in vivo, three different ypes (Fig. 1) of 
34A-immunoliposomes or 14-immunoliposomes with simi- 
lar numbers of antibody molecules per liposome were 
prepared and their targetability and biodistribution were 
evaluated in mice. The characteristics of all immunolipo- 
somes used in this experiment are summarized in Table 1. 
PEG content in the lipid bilayer was set at 6 mol% of the 
total lipid for Type B and C, respectively, to facilitate 
direct comparison with previous results. In this experi- 
ment, Type A, B and C 34A-immunoliposomes contained 
approx. 35, 30 and 30 antibody molecules per liposome, 
respectively. In the case of 14-immunoliposomes, Type A, 
B and C had approx. 21, 22 and 15 antibody molecules per 
vesicle, respectively. Liposome aggregation was not ob- 
served. 
Lung binding of the three types of 34A-immunolipo- 
somes was examined 30 min and 6 h after i.v. injection 
and was expressed as percent of injected dose (Fig. 3). 
Type A 34A-immunoliposome with an average of 35 
antibody molecules per liposome accumulated 42.5% of 
the injected dose in the lung at 30 min. Type B 34A-im- 
munoliposomes which were prepared by incorporating 
DSPE-PEG with an average molecular weight of 2000 into 
Type A immunoliposomes showed a lower level of target 
binding and a significantly higher blood level than those of 
Type A. 6 h after injection, 43.7% of the dose of Type B 
immunoliposomes remained in the blood, a value much 
higher than that of the Type A immunoliposomes. In the 
case of Type C 34A-immunoliposomes with 30 antibody 
molecules per vesicle, the degree of target binding to the 
lung was 56.6% of injected ose at 30 min, 1.3-fold higher 
than that of Type A. Furthermore, Type C immunolipo- 
somes were better retained in the lung than the Type A 
immunoliposomes at 6 h after injection (Fig. 3): Type C 
34A-immunoliposomes showed about 29% dissociation of 
the bound immunoliposomes at 6 h, whereas Type A 
34A-immunoliposomes showed 41% loss of the bound 
immunoliposomes over the same time period. 
The 14 rat monoclonal antibody is a nonspecific anti- 
Table 1 
Characteristics of the three type~ of immunoliposomes 
34A-Immunoliposomes 14-Immunoliposomes 
Type A Type B Type C Type A Type B Type C 
PEG content (tool% of total lipid) 0 6 6 0 
Mean diameter (nm) 121 111 122 97 
Initial antibody: lipid ratio (w/w) 1:6 1:6 1:5 1:4 
Conjugation efficiency (%) 35.6 31.8 24.8 15.2 






a The average number of antibody molecules per liposome was estimated byRef. [20]. See details in the text. 
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Fig. 3. Immunotargetability and biodistribution of 34A- and 14-immuno- 
liposomes at 30 min and 6 h after intravenous injection. Type A, B and C 
34A-immunoliposomes contained approx. 35, 30 and 30 antibody 
molecules per liposome, respectively. Type A, B and C 14-immunolipo- 
somes contained 21, 22 and 15 antibody molecules per liposome, respec- 
tively. Data are expressed as mean+S.D. (n = 3). 
body, but its subtype is the same as that of the 34A 
antibody. By using this nonspecific antibody in the three 
different types of immunoliposomes, we should be able to 
estimate whether the steric barrier imposed by PEG is 
responsible for prolongation of the circulation time and 
avoidance of RES uptake of immunoliposomes. A  shown 
in Table 1, the three types of 14-immunoliposome w re 
prepared with similar numbers of antibody molecules (15- 
20 antibodies/liposome). A high liver accumulation of 
Type A and C 14-immunoliposomes wa  observed, whereas 
liver uptake of Type B was low (Fig. 3). Type B and C 
14-immunoliposomes showed high blood levels up to 6 h 
after injection, whereas Type A showed a low blood level 
at 6 h. These results uggest that although the liver is still 
the major organ for immunoliposome (Type A) uptake, the 
presence of PEG on the immunoliposome surface (Type B) 
interferes terically with the liver uptake, prolonging the 
circulation time. Linkage of antibodies to the PEG terminal 
(Type C) reduced the blood level and increased the liver 
uptake compared with those of Type B. 
3.3. Target binding of 34A-immunoliposomes as a function 
of antibody content 
The efficiency of Type C 34A-immunoliposome bind- 
ing to the target was evaluated as a function of the 
antibody content. A series of Type C 34A-immunolipo- 
somes was prepared with various initial antibody-to-lipid 
ratios. The final number of antibody molecules per lipo- 
some varied from 0 to 74, but the average size of immuno- 
liposomes tayed approximately the same, 90-130 nm in 
diameter. It is clear from the data in Fig. 4 that the 
efficiency of lung targeting was dependent on the antibody 
content of the immunoliposomes. Liposomes containing 
small numbers of antibody molecules per liposome accu- 
mulated in the lung at low levels and were retained in the 
blood at high levels, whereas liposomes linking an average 
of 74 antibody molecules per liposome on the PEG termi- 
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Fig. 4. Effect of the number of antibody molecules per liposome on the 
biodistribution of 34A-Type C immunoliposomes. Liposomes (200 #g of 
lipid) labeled with 67Ga-DF were injected into mice via the tail vein. 
Percent of injected dose_+S.D. (n = 3) in each organ was measured 30 
min after injection. 
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Fig. 5. Comparison of target binding to the lung among the three types of 
34A-immunoliposomes with various numbers of antibody molecules per 
liposome. Lung binding (% of dose) was measured 30 rain after injection. 
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their blood resident amount was only 7% of the injected 
dose. Lung binding reached a plateau at about 30 antibody 
molecules per liposome; further increase in antibody con- 
tent only resulted in the increased liver uptake. Thus, 
antibody density is an important factor for target binding. 
At low numbers of antibody molecules per liposome, such 
as 2 and 9 molecules, free PEG favors evasion of RES 
uptake of the liposomes, resulting in high blood residence 
of Type C 34A-immunoliposome together with a low 
efficiency of target binding due to the low antibody con- 
tent. 
A portion of data in Fig. 4 is plotted in Fig. 5 to 
compare the degree of target binding of the three types of 
34A-immunoliposomes to the lung as a function of the 
antibody content. Type C showed higher immunotar- 
getability than Type A and B at low antibody content (less 
than 30 antibody molecules per vesicle). Thus, Type C is 
accumulated more effectively in the lung than the other 
immunoliposomes, in spil;e of the low antibody content. At 
high antibody content, Type A immunoliposomes also 
showed high level of target accumulation. 
4. Discussion 
We have introduced and tested a new type of long-cir- 
culating immunoliposome (Type C) which can effectively 
bind to the designated target site in vivo. This was achieved 
by the use of newly synthesized DSPE-PEG-COOH to 
couple antibodies (for targeting) directly to the distal ter- 
minal of PEG chains (which allow the liposomes to evade 
the RES and achieve pro]Longed circulation). The method is 
relatively simple and should be widely applicable. 
We have previously demonstrated that 34A-immuno- 
liposome (Type A) binding to the lung target is very rapid, 
and the surface density of antibody on the liposomes is an 
important factor determining the level of target binding of 
immunoliposomes [3]. Furthermore, we showed that the 
inclusion of GM1 in the liposomes enhanced the target 
binding of 34A-immunoliposomes (Type B) as a result of 
elevated blood concentration of the liposomes [9]. Studies 
in vivo revealed that the major competing process for 
immunoliposome target binding is uptake by the RES [9]. 
Long-circulating liposomes can also be obtained by incor- 
porating PEG in place of GM1 [4-8]. However, inclusion 
of PEG reduced the taIget binding of immunoliposomes 
(Type B). This effect depended on the chain length of 
PEG, suggesting that although PEG prolongs the circula- 
tion time of immunoliposomes (Fig. 3), it sterically hinders 
the binding of immtmoliposomes to the target sites 
[10,11,23,24]. Mori et ~d. [11] and Ahmad et al. [23,24] 
suggested using shorter PEG (1900 or 2000 average 
molecular weight), but this still tended to suppress the 
antibody-antigen i teraction (Fig. 3). We [10] and others 
[12] proposed that the use of longer PEG with antibodies 
attached at the distal terminal of the PEG chain would 
afford immunoliposomes with both prolonged circulation 
time and good target binding (Fig. 1, Type C). 
The targeting efficiency of 34A-Type C liposomes was 
also dependent on the number of antibodies per liposome, 
as shown in Figs. 4 and 5. It is noteworthy that Type C 
showed much higher targetability than Type A at less than 
30 antibody molecules per liposome. This is probably due 
to the free PEG chains effectively hindering the RES 
uptake of liposomes, resulting in elevated blood concentra- 
tion of the liposomes. Thus, the presence of free PEG- 
COOH (not linked to antibody) on the Type C immunoli- 
posome surface does not interfere with the binding of the 
terminally linked antibody to antigen and, instead, en- 
hances the target binding of immunoliposomes owing to its 
prolonging effect on the circulation time of the liposomes. 
The combination of using amphipathic PEG to suppress 
the RES uptake rate and attaching a large number of 
antibody molecules to the PEG terminal to enhance the 
target binding rate produced an unprecedentedly high level 
of target binding of liposomes. 
Other studies have shown, however, that a coating of 
intact IgG molecules on liposome surfaces enhances RES 
uptake by an Fc receptor-mediated mechanism [1,2]. In- 
deed, 14-Type C showed a high liver uptake, suggesting 
that this phenomenon occurs in our case. Data in Fig. 4 
also indicate that Type C immunoliposomes with very high 
34A antibody content did not bind with the target with 
superior efficiency. This is probably because the rate of 
liver uptake of these liposomes is sufficiently high to 
compete with the binding with the lung target. To over- 
come this problem, it may be necessary to use Fab or 
F(ab) 2 fragment to avoid the Fc-receptor mediated binding 
of immunoliposomes. Experiments by Blume et al. [15], in 
which plasminogen was linked to the PEG terminal 
(plasminogen-Type C liposome), also resulted in a small 
increase in clearance of the proteoliposomes compared to 
plasminogen-Type B liposomes, but the plasminogen-Type 
C liposomes till circulated for significantly longer period 
of time than the plasminogen-Type A liposomes. 
It should be noted, however, that the target sites for 
34A-liposomes or plasminogen-liposome [15] are located 
at a readily accessible site, i.e., the vascular endothelial 
surface. For a much less accessible target, such as tumor 
cell surface antigens in a solid tumor, only liposomes with 
a strong steric barrier activity would be expected to circu- 
late long enough to reach the target. It is thus of interest o 
test this new approach in a system where the antigen is in 
a less accessible site. We and others have demonstrated 
that long-circulating liposomes of small size (about 100 
nm mean diameter) and rigid lipid composition showed 
significantly greater accumulation i  solid tumor [25-27]. 
The capillary permeability of the endothelial barrier in 
newly vascularized tumors is significantly greater than that 
of normal organs [28]. Under these circumstances it is 
possible that small Type C immunoliposomes could pre- 
dominantly pass through the leaky tumor endothelium by 
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passive convective transport. Thus, the Type C immunoli- 
posomes with long circulation half-lives could be particu- 
larly effective for targeting solid tumors. 
The observation that the conjugation of antibody di- 
rectly to the PEG terminal provides excellent target bind- 
ing and retention of immunoliposomes suggests that these 
Type C liposomes have great potential as a targeted rug 
delivery vehicle. They should be able to provide a high 
local concentration of the encapsulated drug at the target 
site for a prolonged period of time. Unwanted toxic effects 
of the drug in other tissues and cells may also be reduced. 
This is particularly important with the highly toxic antitu- 
mor drugs used in cancer chemotherapy. 
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